Author:
Zhou Ning,Ji Zhili,Li Fengjuan,Qiao Bokang,Lin Rui,Jiang Wenxi,Zhu Yuexin,Lin Yuwei,Zhang Kui,Li Shuanglei,You Bin,Gao Pei,Dong Ran,Wang Yuan,Du Jie
Abstract
BackgroundMitral valve surgery (MVS) is an effective treatment for mitral valve diseases. There is a lack of reliable personalized risk prediction models for mortality in patients undergoing mitral valve surgery. Our aim was to develop a risk stratification system to predict all-cause mortality in patients after mitral valve surgery.MethodsDifferent machine learning models for the prediction of all-cause mortality were trained on a derivation cohort of 1,883 patients undergoing mitral valve surgery [split into a training cohort (70%) and internal validation cohort (30%)] to predict all-cause mortality. Forty-five clinical variables routinely evaluated at discharge were used to train the models. The best performance model (PRIME score) was tested in an externally validated cohort of 220 patients undergoing mitral valve surgery. The model performance was evaluated according to the area under the curve (AUC). Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were compared with existing risk strategies.ResultsAfter a median follow-up of 2 years, there were 133 (7.063%) deaths in the derivation cohort and 17 (7.727%) deaths in the validation cohort. The PRIME score showed an AUC of 0.902 (95% confidence interval [CI], 0.849–0.956) in the internal validation cohort and 0.873 (95% CI: 0.769–0.977) in the external validation cohort. In the external validation cohort, the performance of the PRIME score was significantly improved compared with that of the existing EuroSCORE II (NRI = 0.550, [95% CI 0.001–1.099], P = 0.049, IDI = 0.485, [95% CI 0.230–0.741], P < 0.001).ConclusionMachine learning-based model (the PRIME score) that integrate clinical, demographic, imaging, and laboratory features demonstrated superior performance for the prediction of mortality patients after mitral valve surgery compared with the traditional risk model EuroSCORE II.Clinical Trial Registration[http://www.clinicaltrials.gov], identifier [NCT05141292].
Subject
Cardiology and Cardiovascular Medicine
Reference31 articles.
1. Mitral valve disease–current management and future challenges.;Nishimura;Lancet.,2016
2. Robotic mitral valve repair: indication for surgery does not influence early outcomes.;Maltais;Mayo Clin Proc.,2019
3. ESC working group on valvular heart disease position paper: assessing the risk of interventions in patients with valvular heart disease.;Rosenhek;Eur Heart J.,2012
4. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines.;Otto;Circulation.,2021
5. ESC/EACTS guidelines for the management of valvular heart disease.;Vahanian;Eur Heart J.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献